The rare disease clinical trials market size is projected to be valued at US$ 12,566.14 million in 2023 and is expected to rise to US$ 31,715.25 million by 2033. The sales of rare disease clinical trials are expected to record a significant CAGR of 9.7% during the forecast period.
Various Factors Propelling the Demand for Rare Disease Clinical Trials
The rare disease clinical trials market refers to the development of drugs and therapies for the treatment of rare diseases. These diseases, by definition, affect a small percentage of the population. Consequently, there is often limited research and development in this area.
Clinical trials for rare diseases can be challenging due to the small patient population, limited natural history data, and a lack of standardized endpoints. However, the market is growing due to increased funding and attention to the development of treatments for these diseases.
For example, The Orphan Drug Act was passed in the United States in 1983. The act was enacted to offer financial incentives to pharmaceutical companies to develop treatments for rare diseases.
The advancement in technology and genomics allows for more targeted treatments and personalized medicine. Additionally, there has been increased collaboration between patient advocacy groups, researchers, and the industry. This collaboration has helped to overcome some challenges of conducting clinical trials in rare diseases.
Overall, the market represents an important area of research and development. As it offers hope for patients with conditions that may have previously been considered untreatable.
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Rare Disease Clinical Trials Market Outlook Compared to 2023 to 2033 Forecast
The rare disease clinical trials market was valued at US$ 11,455.0 million in 2022 with a substantial growth trajectory of 8.9% between the analysis period of 2018 to 2022.
Future Market Insights expects the rare disease clinical trials market to expand at a CAGR of 9.7% during the forecast period of 2023 to 2033. The growth can be attributed to the following reasons
Increased Focus on Gene Therapies: Gene therapies are emerging as a promising treatment option for rare diseases caused by genetic mutations. Several gene therapies have been approved by regulatory authorities and some are in the pipeline.
Growing Interest in RNA-targeted Therapies: These therapies aim to modulate the expression of specific genes. It is also gaining attention as a potential treatment for rare diseases. Several RNA-targeted therapies are currently in development for rare diseases such as spinal muscular atrophy and Huntington's disease.
Increasing Collaboration between Stakeholders: Collaboration between patient advocacy groups, researchers, and industry in the rare disease clinical trials market. This collaboration can overcome some challenges of conducting clinical trials in rare diseases. Moreover, it can help to accelerate the development of new treatments.
Considering the above-mentioned factors, FMI opines, the rare disease clinical trials market is likely to witness a market value of US$ 31,715.25 million by the end of 2033.
Investment Opportunities in the Market
Increasing Use of Precision Medicine: Precision medicine involves tailoring treatments to the specific genetic and molecular characteristics of an individual patient. With advances in genomics and personalized medicine, there is a growing trend towards developing treatments that are targeted towards specific rare diseases.
Growth in the Use of Adaptive Clinical Trial Designs: Adaptive clinical trials allow for changes to be made to the trial design based on interim data. This can help to improve the efficiency of rare disease clinical trials, as it allows for the identification of effective treatments quickly and efficiently.
Emphasis on Patient-centricity: Patient advocacy groups and patient representatives are increasingly involved in the design and implementation of rare disease clinical trials. They ensure that patient perspectives are taken into account.
Use of Real-world Evidence: Real-world evidence, such as data from electronic health records and patient registries, is increasingly being used to supplement clinical trial data in rare disease research. This can help to provide a complete picture of the safety and efficacy of treatments.
Increasing Use of Virtual and Remote Clinical Trials: The COVID-19 pandemic has accelerated the trend toward virtual and remote clinical trials. It also allowed patients to participate in clinical trials from the comfort of their own homes. This has increased patient participation in rare disease clinical trials, which can be challenging due to the small patient population.
Find your sweet spots for generating winning opportunities in this market.
Comparative View of Rare Disease Clinical Trials Market
Rare Disease Clinical Trials Market:
Attributes
Rare Disease Clinical Trials Market
CAGR (2023 to 2033)
9.7%
Market Value (2023)
US$ 12,566.14 million
Growth Factor
The scarcity of drugs for treating rare diseases, advances in personalized medicine, and cell and gene therapies. All these factors are opening up new avenues for the development of new treatments for rare diseases.
Opportunity
An increase in funding for rare disease clinical trials from pharmaceutical and biotech companies, as well as non-profit organizations, is further supporting market growth.
Rare Inflammatory Disease Treatment Market:
Attributes
Rare Inflammatory Disease Treatment Market
CAGR (2023 to 2033)
4.6%
Market Value (2023)
US$ 17,335.8 million
Growth Factor
Increased investment in research and development for various drug developments. Additionally, growing demand for various modes of drug administration, have increased market demand.
Opportunity
Increased investment in R&D for various drug developments. Increased demand for various modes of drug administration has boosted market demand for various rare inflammatory disease treatments.
Infectious Disease Diagnostics Market:
Attributes
Infectious Disease Diagnostics Market
CAGR (2023 to 2033)
7.0%
Market Value (2023)
US$ 3.48 billion
Growth Factor
Diagnosis is the first and most important step in identifying and treating an illness. Scientific advances are transforming the practice of performing quick diagnostics. Ongoing technological breakthroughs might continue to alter the industrial environment during the forecast period.
Opportunity
Several government-funded initiatives are gradually offering free screening and testing all over the world. To raise awareness, properly diagnose illnesses, and reduce the risk of infection.
Category-wise Insights of Rare Disease Clinical Trials
Insights into the Therapeutic Domain
In 2022, the oncology segment held a notable share of 33.9%. A few of the key factors fueling the segment growth are
The high amount of cancer rare disease drug approvals
Increasing clinical trials for cancer treatment
Researchers' growing interest in finding effective treatments for rare cancers.
For example, in January 2023, the USFDA approved atezolizumab (Tecentriq), an immunotherapy drug for advanced alveolar soft part sarcoma patients (ASPS).
During the forecast period, the infectious disease segment is expected to expand at an exponential rate of 10.6%. Acanthamoeba keratitis, Q fever, Marburg virus, and other rare infectious diseases are examples. As these rare diseases are fatal, researchers are hugely interested in developing treatments and vaccines for them. Contact lens wearers are likely to develop Acanthamoeba keratitis. Over 85% of people in the United States wear contact lenses. This increases the risk of disease and fuels the demand for treatment. These factors are assisting segment growth.
High Amount of Clinical Studies is Driving the Phase II Segment
In 2022, Phase II had a notable share of 42.6%. Phase II studies are divided into two parts: the first part includes dose range exploration as well as efficacy studies, while the second part includes dose finalization. Over 100-300 participants are recruited for Phase II clinical trials. The phase II segment had the most registered clinical studies as of November 2022. The ClinicalTrial.gov portal had 72,522 studies registered as of November 2022. The high amount of Phase II clinical trials is driving the segment's growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Regional Analysis
In 2022, North America had a Strong Revenue Share of 49.3%. Highly Developed Healthcare Infrastructure is Providing Significant Opportunity in the United States.
The United States has a well-established regulatory framework for rare disease clinical trials, with the Orphan Drug Act of 1983. It provides incentives for the development of drugs for rare diseases. The FDA's Breakthrough Therapy Designation program has also facilitated the development of drugs for rare diseases. Additionally, the National Institutes of Health (NIH) has established a Rare Diseases Clinical Research Network (RDCRN) to facilitate the conduct of clinical trials for rare diseases.
Europe Market Insight
Europe is a significant market for rare disease clinical trials, with countries like Germany, France, and the United Kingdom accounting for a significant share of the market. The European Medicines Agency (EMA) has been proactive in offering regulatory support for rare disease drug development. Therefore, the support from several agencies has increased the clinical trials in Europe.
Asia Pacific Region is Anticipated to Increase at a Robust Pace of 10.6%
Asia Pacific is a significantly growing market for rare disease clinical trials, with countries like China, Japan, and India emerging as key players. The region offers a substantial patient population and low trial costs compared to Western countries. Making it an attractive destination for colossal clinical trials. However, the regulatory environment in some countries can be challenging, and there is a need for great awareness and education about rare diseases.
Latin America
Latin America is an emerging market for rare disease clinical trials, with countries like Brazil and Mexico. The region offers a diverse patient population and low trial costs compared to North America and Europe. However, there are challenges in terms of regulatory compliance and infrastructure, which can limit the growth of the market.
The Middle East and Africa
The Middle East and Africa region is a small but growing market for rare disease clinical trials. Countries like South Africa and Israel are emerging as key players due to their advanced healthcare infrastructure and supportive regulatory environment. However, there are challenges related to political instability, low awareness about rare diseases, and limited healthcare resources in some parts of the region.
Competitive Landscape - Key Players Operating in the Market
The rare disease clinical trials market is highly competitive, with several global players operating in the space. Some key players in the market include
IQVIA Holdings Inc.: A leading provider of clinical trial services, including patient recruitment and management, data management, and regulatory compliance.
PRA Health Sciences Inc.: A global clinical research organization (CRO) that offers a range of services, including clinical trial management, data management, and regulatory affairs.
PPD Inc.: A leading CRO that provides a range of clinical trial services, including site selection, patient recruitment, and project management.
Syneos Health Inc.: A global CRO that offers a range of services, including clinical trial management, data management, and regulatory affairs.
Charles River Laboratories International Inc.: A provider of preclinical and clinical development services, including toxicology testing and clinical trial management.
Covance Inc.: A leading CRO that offers a range of clinical trial services, including site selection, patient recruitment, and data management.
Parexel International Corporation: A global CRO that provides a range of clinical trial services, including project management, data management, and regulatory affairs.
ICON plc: A provider of clinical trial services, including study design, patient recruitment, and data management.
In addition to these companies, there are many other small CROs and specialized service providers operating in the rare disease clinical trials market. As the market continues to grow, competition among these companies is expected to increase. These players are competing on factors such as service quality, expertise, and pricing.
Scope of the Report
Attribute
Details
Growth Rate
CAGR of 9.7% from 2023 to 2033
Base Year of Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ million and Volume in Units and F-CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends, and Pricing Analysis
Key Segments Covered
By Therapeutic Area
By Sponsor
By Phases
By Region
Regions Covered
North America
Latin America
Europe
East Asia
South Asia
The Middle East & Africa
Oceania
Key Countries Profiled
The United States
Canada
Brazil
Mexico
Germany
Italy
France
The United Kingdom
Spain
Russia
China
Japan
India
GCC Countries
Australia
Key Companies Profiled
Takeda Pharmaceutical Company; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AstraZeneca; Novartis AG; LabCorp; IQVIA, Inc.; Charles River Laboratories; Icon PLC; Parexel International Corporation
Customization & Pricing
Available upon Request
Key Segments Covered
Therapeutic Area Outlook:
Oncology
Cardiovascular Disorders
Neurological Disorders
Infectious Disease
Genetic Disorders
Autoimmune And Inflammation
Hematologic Disorders
Musculoskeletal Disorders
Others
Phase Outlook:
Phase I
Phase II
Phase III
Phase IV
Sponsor Outlook:
Pharmaceutical & Biopharmaceutical Companies
Non-profit Organizations
Others
By Region:
North America
Latin America
Western Europe
Eastern Europe
Asia Pacific excluding Japan (APEJ)
Japan
The Middle East & Africa (MEA)
Frequently Asked Questions
How Big is the Rare Disease Clinical Trials Market?
The market is valued at US$ 12.5 billion in 2023.
Who are the Top Market Players?
Pfizer, Inc., AstraZeneca, and Novartis AG are the top market players.
How was the Historical Performance of the Market?
The market held a CAGR of 8.9% from 2018 to 2022.
What Opportunities Await the Market Players?
Advancements in personalized medicine to boost market growth.
Which is the Leading Segment by Phase Outlook?
Phase II segment is likely to remain preferred through 2033.
Table of Content
1. Executive Summary | Rare Disease Clinical Trials Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Area
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033
5.3.1. Oncology
5.3.2. Cardiovascular Disorders
5.3.3. Neurological Disorders
5.3.4. Infectious Disease
5.3.5. Genetic Disorders
5.3.6. Autoimmune And Inflammation
5.3.7. Hematologic Disorders
5.3.8. Musculoskeletal Disorders
5.3.9. Others
5.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Phase
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Phase, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Phase, 2023 to 2033
6.3.1. Phase I
6.3.2. Phase II
6.3.3. Phase III
6.3.4. Phase IV
6.4. Y-o-Y Growth Trend Analysis By Phase, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Phase, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sponsor
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Sponsor, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sponsor, 2023 to 2033
7.3.1. Pharmaceutical & Biopharmaceutical Companies
7.3.2. Non-profit Organizations
7.4. Y-o-Y Growth Trend Analysis By Sponsor, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Sponsor, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Therapeutic Area
9.2.3. By Phase
9.2.4. By Sponsor
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Therapeutic Area
9.3.3. By Phase
9.3.4. By Sponsor
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Therapeutic Area
10.2.3. By Phase
10.2.4. By Sponsor
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapeutic Area
10.3.3. By Phase
10.3.4. By Sponsor
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Therapeutic Area
11.2.3. By Phase
11.2.4. By Sponsor
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapeutic Area
11.3.3. By Phase
11.3.4. By Sponsor
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Therapeutic Area
12.2.3. By Phase
12.2.4. By Sponsor
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapeutic Area
12.3.3. By Phase
12.3.4. By Sponsor
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Therapeutic Area
13.2.3. By Phase
13.2.4. By Sponsor
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapeutic Area
13.3.3. By Phase
13.3.4. By Sponsor
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Therapeutic Area
14.2.3. By Phase
14.2.4. By Sponsor
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Therapeutic Area
14.3.3. By Phase
14.3.4. By Sponsor
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Therapeutic Area
15.2.3. By Phase
15.2.4. By Sponsor
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Therapeutic Area
15.3.3. By Phase
15.3.4. By Sponsor
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Therapeutic Area
16.1.2.2. By Phase
16.1.2.3. By Sponsor
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Therapeutic Area
16.2.2.2. By Phase
16.2.2.3. By Sponsor
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Therapeutic Area
16.3.2.2. By Phase
16.3.2.3. By Sponsor
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Therapeutic Area
16.4.2.2. By Phase
16.4.2.3. By Sponsor
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Therapeutic Area
16.5.2.2. By Phase
16.5.2.3. By Sponsor
16.6. United kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Therapeutic Area
16.6.2.2. By Phase
16.6.2.3. By Sponsor
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Therapeutic Area
16.7.2.2. By Phase
16.7.2.3. By Sponsor
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Therapeutic Area
16.8.2.2. By Phase
16.8.2.3. By Sponsor
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Therapeutic Area
16.9.2.2. By Phase
16.9.2.3. By Sponsor
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Therapeutic Area
16.10.2.2. By Phase
16.10.2.3. By Sponsor
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Therapeutic Area
16.11.2.2. By Phase
16.11.2.3. By Sponsor
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Therapeutic Area
16.12.2.2. By Phase
16.12.2.3. By Sponsor
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Therapeutic Area
16.13.2.2. By Phase
16.13.2.3. By Sponsor
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Therapeutic Area
16.14.2.2. By Phase
16.14.2.3. By Sponsor
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Therapeutic Area
16.15.2.2. By Phase
16.15.2.3. By Sponsor
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Therapeutic Area
16.16.2.2. By Phase
16.16.2.3. By Sponsor
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Therapeutic Area
16.17.2.2. By Phase
16.17.2.3. By Sponsor
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Therapeutic Area
16.18.2.2. By Phase
16.18.2.3. By Sponsor
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Therapeutic Area
16.19.2.2. By Phase
16.19.2.3. By Sponsor
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Therapeutic Area
16.20.2.2. By Phase
16.20.2.3. By Sponsor
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Therapeutic Area
16.21.2.2. By Phase
16.21.2.3. By Sponsor
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Therapeutic Area
17.3.3. By Phase
17.3.4. By Sponsor
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Takeda Pharmaceutical Company
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. F. Hoffmann-La Roche Ltd.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Pfizer, Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. AstraZeneca
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Novartis AG
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. LabCorp
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. IQVIA
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Charles River Laboratories Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Icon PLC
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Parexel International Corporation
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Phase, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Sponsor, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Phase, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Sponsor, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Phase, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Sponsor, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Phase, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Sponsor, 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Phase, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by Sponsor, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Phase, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Sponsor, 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Phase, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by Sponsor, 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Therapeutic Area, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Phase, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Sponsor, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Therapeutic Area, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Phase, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Sponsor, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Phase, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Phase, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Phase, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Sponsor, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Sponsor, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Sponsor, 2023 to 2033
Figure 17: Global Market Attractiveness by Therapeutic Area, 2023 to 2033
Figure 18: Global Market Attractiveness by Phase, 2023 to 2033
Figure 19: Global Market Attractiveness by Sponsor, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Therapeutic Area, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Phase, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Sponsor, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Phase, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Phase, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Phase, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Sponsor, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Sponsor, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Sponsor, 2023 to 2033
Figure 37: North America Market Attractiveness by Therapeutic Area, 2023 to 2033
Figure 38: North America Market Attractiveness by Phase, 2023 to 2033
Figure 39: North America Market Attractiveness by Sponsor, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Therapeutic Area, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Phase, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Sponsor, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Phase, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Phase, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Phase, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Sponsor, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Sponsor, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Sponsor, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Therapeutic Area, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Phase, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Sponsor, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Therapeutic Area, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Phase, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Sponsor, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Phase, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Phase, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Phase, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Sponsor, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Sponsor, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Sponsor, 2023 to 2033
Figure 77: Europe Market Attractiveness by Therapeutic Area, 2023 to 2033
Figure 78: Europe Market Attractiveness by Phase, 2023 to 2033
Figure 79: Europe Market Attractiveness by Sponsor, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Therapeutic Area, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Phase, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by Sponsor, 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Phase, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Phase, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Phase, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by Sponsor, 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Sponsor, 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Sponsor, 2023 to 2033
Figure 97: South Asia Market Attractiveness by Therapeutic Area, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Phase, 2023 to 2033
Figure 99: South Asia Market Attractiveness by Sponsor, 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Therapeutic Area, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Phase, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Sponsor, 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Phase, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Phase, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Phase, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Sponsor, 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Sponsor, 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Sponsor, 2023 to 2033
Figure 117: East Asia Market Attractiveness by Therapeutic Area, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Phase, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Sponsor, 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Therapeutic Area, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Phase, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by Sponsor, 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Phase, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Phase, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Phase, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by Sponsor, 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Sponsor, 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Sponsor, 2023 to 2033
Figure 137: Oceania Market Attractiveness by Therapeutic Area, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Phase, 2023 to 2033
Figure 139: Oceania Market Attractiveness by Sponsor, 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Therapeutic Area, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Phase, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by Sponsor, 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Therapeutic Area, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Therapeutic Area, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Therapeutic Area, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Phase, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Phase, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Phase, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by Sponsor, 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Sponsor, 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Sponsor, 2023 to 2033
Figure 157: MEA Market Attractiveness by Therapeutic Area, 2023 to 2033
Figure 158: MEA Market Attractiveness by Phase, 2023 to 2033
Figure 159: MEA Market Attractiveness by Sponsor, 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
